相关实验视频

Updated: Jul 24, 2025

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

对复发的上皮卵巢癌治疗的pegylated脂质体 doxorubicin

Rebecca Newhouse¹, Ellen Nelissen², Karim Hussien El-Shakankery³

¹Department of Gynaecological Oncology, Musgrove Park Hospital, Taunton, UK.

The Cochrane database of systematic reviews

|July 5, 2023

概括

结合化疗中的pegylated liposomal doxorubicin (PLD) 可能改善敏感性复发性卵巢癌的无进展生存率,但在整体生存率上几乎没有差异. 对于白金耐药性疾病,单独使用PLD是有效的,而组合增加副作用而没有显著的生存益处.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

卵巢癌通常是晚诊断的,对于复发病例的治疗选择有限.
维持生活质量对于复发性上皮卵巢癌 (EOC) 患者至关重要.
化脂体 doxorubicin (PLD) 是复发性EOC的一种化疗选择.

研究的目的:

评估单独或与其他药物结合使用的PLD的疗效和安全性,用于复发性高度上皮卵巢癌 (EOC) 的女性.

主要方法:

26项随机对照试验 (RCT) 的系统审查和元分析,涉及8277名参与者.
搜索了多个数据库 (CENTRAL,MEDLINE,Embase) 和临床试验登记册.
评估偏差风险和关键比较的证据确定性.

主要成果:

对于敏感性复发性EOC,PLD加化疗可能会改善无进展生存率,但与其他组合相比,整体生存率几乎没有差异.
单独使用PLD可与用于抗复发性EOC的其他化疗相美.
对PLD与其他抗EOC药物的联合治疗显示严重不良事件和贫血增加,生存益处有限.

结论:

含有PLD的疗法在敏感性复发性EOC中提供潜在的无进展生存益处,治疗选择以患者因素为指导.
单剂PLD仍然是白金耐药复发性EOC的可行选择.
将PLD与耐药EOC中的其他药物结合起来,会增加毒性,但没有明显的生存优势.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...